Additional file 3 of Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
收藏数据链接：
官方服务：
资源简介：
Additional file 3: Table S1. Clinicopathological information for pembrolizumab-treated HCC patients.
创建时间：
2022-01-06
